HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $40 price target.